Ex-Pfizer R&D Chief Warns of Biopharma's Future Risks
TL;DR
The former head of Pfizer R&D expresses concern about the future of the biopharma industry, highlighting past optimism about a productivity surge driven by genomic advances and new drug modalities, but implying that these expectations may not have been realized as hoped.
Topics:healthbusiness#biopharma-future#business#drug-discovery#pfizer#pharmaceutical-industry#randd-productivity
Want the full story? Read the original reporting
Read on statnews.com